New Vaccines Against Otitis Media: Projected Benefits and Cost-effectiveness
The DOI matches its Crossref record.
Abstract
OBJECTIVE. New vaccines that offer protection against otitis media caused by nontypeable Haemophilus influenzae and by Moraxella catarrhalis are under development. However, the potential health benefits and economic effects of such candidate vaccines have not been systematically assessed. METHODS. We created a computerized model to compare the projected benefits and costs of (1) the currently available 7-valent pneumococcal conjugate vaccine, (2) a candidate pneumococcal–nontypeable H influenzae vaccine that has been tested in Europe, (3) a hypothetical pneumococcal-nontypeable H influenzae–Moraxella vaccine, and (4) no vaccination. The clinical probabilities of acute otitis media and of otitis media with effusion were generated from multivariate analyses of data from 2 large health maintenance organizations and from the Pittsburgh Child Development/Otitis Media Study cohort. Other probabilities, costs, and quality-of-life values were derived from published and unpublished sources. The base-case analysis assumed vaccine dose costs of $65 for the 7-valent pneumococcal conjugate vaccine, $100 for the pneumococcal-nontypeable H influenzae vaccine, and $125 for the pneumococcal-nontypeable H influenzae–Moraxella vaccine. RESULTS. With no vaccination, we projected that 13.7 million episodes of acute otitis media would occur annually in US children aged 0 to 4 years, at an annual cost of $3.8 billion. The 7-valent pneumococcal conjugate vaccine was projected to prevent 878000 acute otitis media episodes, or 6.4% of those that would occur with no vaccination; the corresponding value for the pneumococcal–nontypeable H influenzae vaccine was 3.7 million (27%) and for the pneumococcal–nontypeable H influenzae–Moraxella vaccine was 4.2 million (31%). Using the base-case vaccine costs, pneumococcal–nontypeable H influenzae vaccine use would result in net savings compared with nontypeable 7-valent pneumococcal conjugate use. Conversely, pneumococcal–nontypeable H influenzae–Moraxella vaccine use would not result in savings compared with pneumococcal–nontypeable H influenzae vaccine use, but would cost $48 000 more per quality-adjusted life-year saved. The results were sensitive to variations in assumptions on vaccine effectiveness and vaccine dose costs but not to variations in other assumptions. CONCLUSIONS. New candidate vaccines against otitis media have the potential to prevent millions of disease episodes in the United States annually. If priced comparably with other recently introduced vaccines, these new otitis vaccines could achieve cost-effectiveness comparable with or more favorable than that of the 7-valent pneumococcal conjugate vaccine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Clinical Practice Guideline: Otitis Media with Effusion (Update)
Rosenfeld, R. M., Shin, J. J., Schwartz, S. R., Coggins, R., Gagnon, L., Hackell, J. M., Hoelting, D., Hunter, L. L., Kummer, A. W., Payne, S. C., et al. (2016) · Otolaryngology–Head and Neck Surgery · doi:10.1177/0194599815623467 · Cited by 2,006
The Diagnosis and Management of Acute Otitis Media
Lieberthal, A. S., Carroll, A. E., Chonmaitree, T., Ganiats, T. G., Hoberman, A., Jackson, M. A., Joffe, M. D., Miller, D. T., Rosenfeld, R. M., Sevilla, X. D., et al. (2013) · Pediatrics · doi:10.1542/peds.2012-3488 · Cited by 1,645
Otitis media and its consequences: beyond the earache
Vergison, A., Dagan, R., Arguedas, A., Bonhoeffer, J., Cohen, R., DHooge, I., Hoberman, A., Liese, J., Marchisio, P., Palmu, A. A., et al. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70012-8 · Cited by 341
Self-citationFlynn (2009) · doi:10.3310/hta18600 · Cited by 17
Metadata
- Authors
- O'Brien, M. A., Prosser, L. A., Paradise, J. L., Ray, G. T., Kulldorff, M., Kurs-Lasky, M., Hinrichsen, V. L., Mehta, J., Colborn, D. K., & Lieu, T. A.
- Venue
- Pediatrics
- Publisher
- American Academy of Pediatrics (AAP)
- Published
- 2009-06-01
- Volume
- 123
- Issue
- 6
- Pages
- 1452-1463
- ISSN
- 0031-4005 (ISSN-L)
- 1098-4275
- OpenAlex
- W1980070970
- Cited by
- 67
- References
- 0
- FWCI
- 5.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New Vaccines Against Otitis Media: Projected Benefits and Cost-effectiveness. https://app.cochat.ai/papers/10.1542/peds.2008-1482
- The paper
- O'Brien, M. A., Prosser, L. A., Paradise, J. L., Ray, G. T., Kulldorff, M., Kurs-Lasky, M., Hinrichsen, V. L., Mehta, J., Colborn, D. K., & Lieu, T. A. (2009). New Vaccines Against Otitis Media: Projected Benefits and Cost-effectiveness. Pediatrics. https://doi.org/10.1542/peds.2008-1482
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.